The 107,000-sq-ft facility is expected to be completed in 2022. The location is the first U.S. biomanufacturing facility for WuXi. According to the company, the campus will be located on a 46-acre plot and will create 150 new jobs for the local economy.
WuXi is a Hong-Kong based drug discovery and clinical and commercial manufacturing organization. It currently has over 100 projects in phase I and II clinical development and 16 in phase III development, as well as one project in commercial manufacturing.
Copyright © 2020 scienceboard.net